- Home
- ASH vs CGON Comparison
ASH vs CGON Comparison
Compare ASH & CGON Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ASH
- CGON
- Stock Information
- Founded
- ASH 1924
- CGON 2010
- Country
- ASH United States
- CGON United States
- Employees
- ASH N/A
- CGON N/A
- Industry
- ASH Specialty Chemicals
- CGON
- Sector
- ASH Consumer Discretionary
- CGON
- Exchange
- ASH Nasdaq
- CGON NYSE
- Market Cap
- ASH 2.3B
- CGON 2.0B
- IPO Year
- ASH N/A
- CGON 2024
- Fundamental
- Price
- ASH $53.39
- CGON $26.51
- Analyst Decision
- ASH Buy
- CGON Strong Buy
- Analyst Count
- ASH 5
- CGON 10
- Target Price
- ASH $70.50
- CGON $64.44
- AVG Volume (30 Days)
- ASH 553.6K
- CGON 809.8K
- Earning Date
- ASH 08-05-2025
- CGON 08-07-2025
- Dividend Yield
- ASH 3.05%
- CGON N/A
- EPS Growth
- ASH N/A
- CGON N/A
- EPS
- ASH N/A
- CGON N/A
- Revenue
- ASH $1,949,000,000.00
- CGON $662,000.00
- Revenue This Year
- ASH N/A
- CGON N/A
- Revenue Next Year
- ASH $2.35
- CGON $25,206.93
- P/E Ratio
- ASH N/A
- CGON N/A
- Revenue Growth
- ASH N/A
- CGON 224.51
- 52 Week Low
- ASH $45.21
- CGON $14.80
- 52 Week High
- ASH $98.44
- CGON $40.47
- Technical
- Relative Strength Index (RSI)
- ASH 56.60
- CGON 54.72
- Support Level
- ASH $52.34
- CGON $25.80
- Resistance Level
- ASH $55.44
- CGON $27.56
- Average True Range (ATR)
- ASH 1.56
- CGON 1.00
- MACD
- ASH 0.35
- CGON 0.04
- Stochastic Oscillator
- ASH 70.80
- CGON 67.97
About ASH Ashland Inc.
Ashland Inc is a world-wide specialty materials company that serves a wide range of industrial markets. The company has a business-centric operating model and is organized into four distinct segments: life sciences, personal care, specialty additives, and intermediates. Key customers for the firm include pharmaceutical companies and manufacturers of personal care products, food and beverages, and nutraceuticals and supplements. The life sciences segment derives maximum revenue. The company generates its sales from North America, Europe, Asia Pacific, and Latin America, and Others.
About CGON CG ONCOLOGY INC
CG Oncology Inc is a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients afflicted with bladder cancer. The company's lead candidate, cretostimogene grenadenorepvec, is a targeted oncolytic intravesically delivered immunotherapy agent that is in two phase three trials (one high-risk BCG unresponsive NMIBC trial and one intermediate-risk NMIBC trial) and a phase two clinical study with a checkpoint inhibitor for high-risk BCG unresponsive NMIBC disease.